The gene recently cloned that is responsible for the Pendred syndrome (PDS), an autosomal recessive disease characterized by goiter and congenital sensorineural deafness, is mainly expressed in the thyroid gland. Its product, designated pendrin, was shown to transport chloride and iodide. To investigate whether the PDS gene is altered during thyroid tumorigenesis, PDS gene expression and pendrin expression were studied using real-time kinetic quantitative PCR and antipeptide antibodies, respectively, in normal, benign, and malignant human thyroid tissues. The results were then compared to those observed for sodium/iodide symporter (NIS) expression.
T HE GENE responsible for Pendred syndrome (PDS), an
autosomal recessive disease characterized by goiter and congenital sensorineural deafness, has recently been identified (1) . The PDS gene is located on chromosome 7q31 and encodes a 5-kb transcript that is mainly expressed in the thyroid gland (2, 3) . The PDS gene product, pendrin, is a highly hydrophobic transmembrane protein composed of 780 amino acids. On the basis of sequence homology, it was first suggested that pendrin might belong to the sulfate anion transporter family, composed of the human diastrophic dysplasia sulfate transporter (4) and the human sulfate transporter down-regulated in adenoma (5) . More recently, pendrin was shown to transport chloride and iodide, but not sulfate, thereby emphasizing a potential critical role for this protein in thyroid physiology (6, 7) . This is in agreement with previous in vitro and in vivo findings showing that iodine organification was altered in thyroid cells obtained from a patient with PDS (8) .
The iodine pathway comprises several steps in thyroid cells that involve an iodide transport mechanism via the sodium/iodide symporter (NIS) (9) , iodide organification into the thyroglobulin (Tg) molecule at the apical pole that is mediated by the thyroid peroxidase (TPO), and thyroid hormone synthesis and secretion (10, 11) . Biochemical abnormalities that affect the complex process of thyroid hormone synthesis have been demonstrated in differentiated thyroid cancers (DTC) (12, 13) . In vivo, DTC usually appear as hypofunctioning cold nodules on the thyroid scintiscan, indicating impaired radioiodine trapping ability, but they retain the capacity to synthesize Tg and to respond to TSH stimulation (14) . In vitro studies of tumor cells revealed a low concentration of intracellular iodine, reduced Tg iodination, decreased TPO activity, and a low rate of thyroid hormone synthesis (15) .
A defective iodide-trapping mechanism appears to be an early and constant feature during oncogenic transformation of thyroid cells (16) . Recent reports have shown that this defect is due to reduced NIS gene expression detected in both malignant and benign hypofunctioning thyroid tumors (17) (18) (19) (20) (21) . Other changes in the expression of thyroid-specific genes (TPO, Tg, and TSH receptor) are associated with neoplastic transformation, but are present in only some thyroid tumor phenotypes (21, 22) . In this respect, the demonstration that pendrin serves as an iodide transporter prompted us to investigate whether PDS gene expression may be altered during thyroid tumorigenesis.
We analyzed PDS gene expression using real-time kinetic quantitative PCR (23) and pendrin expression using an immunohistochemical method based on antipeptide antibodies in a series of normal, benign, and malignant human thyroid tissues, in which we recently studied Tg, TPO, TSH receptor, and NIS gene expression (21) .The results of PDS gene ex-pression were then compared to those observed for NIS gene expression, which have been previously reported (21) .
Materials and Methods

Tissue samples
Thyroid tissue samples were selected after histological examination and classified according to WHO recommendations (24) . Tissue samples selected for real-time quantitative PCR were as follows (21): hyperfunctioning tissues, including Graves' thyroid tissues (n ϭ 5) and toxic adenomas (n ϭ 8), benign hypofunctioning thyroid follicular adenomas (n ϭ 24), and differentiated thyroid carcinomas (n ϭ 43), including papillary carcinomas (n ϭ 38) and poorly differentiated and widely invasive follicular carcinomas (n ϭ 5). To obtain calibrator materials for real-time PCR analysis, normal tissue counterparts (n ϭ 5) were carefully microdissected from thyroid glands obtained from five patients with papillary carcinoma. For immunohistochemical analysis, normal thyroid samples (n ϭ 4) and pathological thyroid tissue specimens were selected from the above series, including Graves' thyroid tissues (n ϭ 3), benign hypofunctioning adenomas (n ϭ 5), and papillary carcinomas (n ϭ 8). Specimens were frozen at Ϫ80 C in isopentane and stored in liquid nitrogen before use. Except for the patients with Graves' disease or toxic adenoma, in whom serum TSH was undetectable, thyroid samples were obtained from euthyroid subjects whose serum TSH concentrations were in the normal range at the time of surgery. This study was performed in accordance with protocols previously approved by the local human studies committee.
Peptide synthesis, production, and characterization of antipeptide antiserum to pendrin
A composite peptide spanning the N-terminal (1-16) and the C-terminal (765-780) regions of pendrin was synthesized by a conventional solid phase method using a PE Applied Biosystems model 431A peptide synthesizer (Foster City, CA). The identity and purity of the 1-16/765-780 peptide were verified as previously described (18) . The synthetic peptide was conjugated to keyhole limpet hemocyanin using benzidine as the coupling agent on the 765 Tyr residue. Two rabbits were immunized by intradermal injections of the synthetic peptide-carrier conjugate. After two boosts at 3-week intervals, animals were bled, and their serum specimens were tested in an enzyme-linked immunosorbent assay. Antisera at various dilutions were verified for their capacity to react with the pendrin synthetic peptide coated on microtiter plates. Antibody binding was then revealed by peroxidaselabeled goat antirabbit antibody (Nordic, Tilburg, The Netherlands). The production and characteristics of the antihuman NIS antiserum have been described previously (18) .
Immunohistochemistry
Serial frozen cryostat tissue sections (5 m) were cut and fixed in acetone for 10 min. These sections were then incubated for 30 min with either the antipendrin or anti-NIS antiserum, diluted at 1:75 and 1:500, respectively. Sections were then washed three times in Tris-HCl buffer for 5 min each time and incubated with a biotinylated antibody (K4017, EnVision Labeled Polymer, DAKO Corp., Carpinteria, CA). They were washed again three times and incubated with alkaline phosphatase-labeled streptavidin (DAKO-K674) for 10 min. After three additional washes, staining was completed after incubation with a substrate chromogen solution (DAKO-K699 Fast red). Negative controls were obtained by studying nonthyroid tissues and incubating thyroid sections with preimmune antiserum and immune antiserum preabsorbed with excess corresponding peptide.
Determination of messenger RNA (mRNA) level using realtime PCR
Total RNA was isolated from tissue samples using the DNA/RNA extraction Midi kit according to the manufacturer's instructions (QIA-GEN, Hilden, Germany). The quality of RNA was assessed by conventional gel electrophoresis. Oligonucleotide primers and TaqMan (PE Applied Biosystems) probes were designed to be intron spanning, using the computer program Primer Express (Perkin-Elmer Corp./PE Applied Biosystems). They were purchased from Perkin-Elmer Corp./PE Applied Biosystems, and their sequences are presented in Table 1 . PCR reaction was carried out to produce amplicons that were subsequently analyzed by gel electrophoresis and sequencing. 
Statistical methods
The expression of PDS and NIS genes detected in each histological type was compared with that in normal samples. mRNA expression patterns were compared using the t test, and the correlation between these expression profiles was studied using Spearman's rank order correlation coefficient for each histological type. The level of significance chosen was fixed at 5%.
Results
Production and characterization of antipeptide antiserum to pendrin
Rabbit antiserum titers obtained after immunization with the composite pendrin (1-16/765-780) synthetic peptide-carrier conjugate were determined by enzyme-linked immunosorbent assay. Both animals produced antisera, and competitive inhibition experiments (data not shown) indicated that the affinity of these antisera for the synthetic peptide ranged from 10 Ϫ6 to 5 ϫ 10 Ϫ7 mol/L. The characteristics of the antiserum directed against human NIS have been described previously (18).
Determination of the mRNA level
To validate the real-time PCR method, standard curves for the PDS gene and 18S ribosomal RNA were constructed from PCR products that were serially diluted in nuclease-free H 2 O. Figure 1 shows the amplification plots for the PDS and NIS mRNAs and control 18S RNA. The efficiency of the standard curve, as determined by its slope, allowed us to quantify the PDS gene expression profile in each thyroid specimen by using the comparative threshold cycle (Ct) method according to the manufacturer's instructions. The characteristics of the assay for NIS gene expression have been reported previously (21) . The calibrator was constituted from one sample of normal tissue: it was used as the 1 ϫ sample, and all other levels were expressed as an n-fold difference relative to the calibrator. The intraassay coefficient of variation was less than 1%.
PDS gene and pendrin expression in normal thyroid tissues
Among the five specimens of normal thyroid tissue, mean and median PDS gene expression levels were similar ( Fig. 2 and Table 2 ). Mean and median NIS gene expression levels were also similar in normal thyroid specimens (21) .
PDS and NIS gene products displayed a different location pattern, as shown by immunohistochemical analysis; Results are expressed as an x-fold difference relative to the calibrator. n, Number of samples. Hyperfunctioning thyroid tissues include five samples from patients with Graves' disease and eight toxic adenomas. a Ͻ0.1. b Ͻ0.01.
whereas immunostaining of the NIS protein was restricted to the basolateral membrane, pendrin was localized at the apical pole of thyrocytes (Fig. 3, A and B) . Immunostaining of pendrin was heterogeneous; inside a given follicle, isolated follicular cells were strongly immunostained and were totally distinct from weakly positive or negative cells. A similar staining pattern was observed in all follicles, but some had a higher number of strongly pendrinpositive cells (Fig. 4, A and B) . Similar heterogeneity was observed for NIS protein staining (18) . Stromal cells, lymphocytes, intrafollicular macrophages, and vascular endothelial cells did not react with pendrin or with NIS antibodies.
PDS gene and pendrin expression in hyperfunctioning thyroid tissues
In tissue obtained from thyroid glands affected by Graves' disease and toxic adenomas, PDS mRNA levels were in the normal range, whereas NIS mRNA levels were significantly increased. However, immunohistochemistry showed strong staining in the majority of follicular cells with both antipendrin and anti-NIS antisera (Fig. 4, C and D) .
PDS gene and pendrin expression in hypofunctioning thyroid adenomas
In hypofunctioning adenomas, the mean and median PDS gene expression levels were similar to those detected in nor- mal thyroid tissues. A more than 3-fold decrease was observed in only 5 of 24 hypofunctioning nodules. In contrast, 20 of 24 of these tissue specimens displayed reduced NIS mRNA levels. Pendrin immunostaining was highly variable among these adenomas, ranging from very weak staining to staining similar to that observed in normal thyroid tissues.
PDS gene and pendrin expression in thyroid carcinomas
Profound alterations were detected in the expression of the two target genes in neoplastic thyroid tissues. PDS mRNA expression was 2-to 1000-fold lower (median, 100-fold) than that in normal thyroid tissues. NIS gene expression was decreased to a similar extent. Pendrin immunostaining was weak and was positive in only a small minority of tumor cells (Fig. 4, E and F) . The same pattern of weak staining was observed for NIS.
In contrast to mean NIS expression, which was decreased to the same extent in both hypofunctioning adenomas and differentiated thyroid carcinomas (P ϭ 0.72), mean PDS gene expression was significantly lower in thyroid cancer tissues than in hypofunctioning adenomas (P Ͻ 0.001). In hypofunctioning adenomas, PDS gene expression was not related to that of the NIS gene (P ϭ 0.19), whereas a close relationship was found in malignant thyroid tissues (P Ͻ 0.001).
Discussion
Intrathyroidal iodine metabolism is profoundly altered in thyroid cancer tissues. Previously identified biochemical and , ϫ250) ; the great majority of follicular cells are strongly immunostained with both antibodies. E and F, Papillary carcinoma; low staining with both antibodies (magnification: pendrin, ϫ250; NIS, ϫ200). molecular defects hamper radioiodine concentration in most neoplastic thyroid tumors and account for its absence in approximately a third of thyroid cancer metastases (25) . Our study demonstrates that the pendrin-PDS gene pathway is also impaired in thyroid cancer tissues, and this is consistent with the defective iodine organification found in these tissues (26) .
Pendrin, the predicted protein, was demonstrated to accelerate the transport of chloride and iodide (6) . Defective iodine organification due to an inactivating mutation of the PDS gene is observed in patients with PDS. This results in a goiter, with various degrees of hypothyroidism; an alteration in iodine organification is attested to by a positive perchlorate discharge test and the presence of Tg molecules displaying a normal monomer size but a low hormone and iodine content (27) .
More interestingly, our immunohistochemical study, based on an antipeptide antibody, demonstrated that pendrin is located at the apical pole of thyrocytes. Together with the above-mentioned data, this observation suggests that pendrin is the apical iodide transporter that permits the organification of Tg.
In Graves' thyroid tissues and in toxic adenomas, PDS gene expression was not significantly increased, in contrast to that of NIS and TPO (21) . This suggests that, like Tg mRNA expression, PDS gene expression is less sensitive to the stimulatory effects of the TSH pathway. However, immunohistochemistry showed stronger staining in these tissue specimens than in normal tissues, indicating that pendrin expression is regulated at the transcription level, and that this is increased in these tissues. This finding is in accordance with the increased rate of thyroid hormone synthesis.
In contrast to NIS mRNA and protein levels, which were decreased in both benign and malignant hypofunctioning thyroid tumors, PDS gene and pendrin expression levels appeared to be normal in most hypofunctioning adenomas and were significantly decreased only in differentiated thyroid carcinomas. A highly significant correlation was found between pendrin and NIS gene expression in differentiated thyroid carcinomas. Although the mechanism of this alteration remains to be investigated, these data suggest that the expression of these two genes is regulated by different pathways. These data also suggest that the limited degree of iodination of Tg found in differentiated thyroid carcinoma is related to defects not only in the iodine-trapping ability and in the iodination process through low TPO biochemical activity, but also to low expression of apical pendrin.
In conclusion, our study demonstrates that pendrin is located at the apical membrane of thyrocytes and suggests that it is probably the apical iodide transporter. PDS gene expression is dramatically decreased in DTC, but not in hypofunctioning adenomas. It remains to be established whether and to what extent PDS gene expression constitutes a critical alteration in thyroid tumors.
